You just read:

Azevan Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of SRX246 in Intermittent Explosive Disorder

News provided by

Azevan Pharmaceuticals, Inc.

May 22, 2016, 09:00 ET